Singapore, July 23 -- US-based BostonGene, the developer of the leading AI model for tumour and immune biology, has announced a strategic research partnership with Japan-based Kyoto University, a research institution known for its groundbreaking advancements in medicine and science.

The partnership supports a multicenter, Phase II clinical trial led by Dr Manabu Muto of Kyoto University, evaluating the safety and efficacy of a combined therapeutic approach using immune checkpoint inhibitors (ICI) and photodynamic therapy (PDT) for patients facing advanced gastrointestinal cancers.

The study is being conducted as an investigator-initiated trial with financial support from Meiji Seika Pharma.

BostonGene will apply its multimodal AI analy...